Stock News

FibroGen, Inc. (FGEN) Reaches $46.65 After 4.00% Up Move; Agios Pharmaceuticals (AGIO) SI Increased By 5.46%

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Logo

The stock of FibroGen, Inc. (NASDAQ:FGEN) is a huge mover today! The stock increased 2.75% or $1.25 during the last trading session, reaching $46.65. About 150,348 shares traded. FibroGen, Inc. (NASDAQ:FGEN) has risen 78.19% since May 11, 2017 and is uptrending. It has outperformed by 66.64% the S&P500.The move comes after 9 months positive chart setup for the $3.89B company. It was reported on May, 11 by Barchart.com. We have $48.52 PT which if reached, will make NASDAQ:FGEN worth $155.68 million more.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) had an increase of 5.46% in short interest. AGIO’s SI was 5.59M shares in May as released by FINRA. Its up 5.46% from 5.30 million shares previously. With 400,600 avg volume, 14 days are for Agios Pharmaceuticals Inc (NASDAQ:AGIO)’s short sellers to cover AGIO’s short positions. The SI to Agios Pharmaceuticals Inc’s float is 13.01%. The stock increased 1.12% or $0.95 during the last trading session, reaching $85.82. About 54,373 shares traded. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 41.40% since May 11, 2017 and is uptrending. It has outperformed by 29.85% the S&P500.

Investors sentiment increased to 1.22 in 2017 Q4. Its up 0.01, from 1.21 in 2017Q3. It increased, as 19 investors sold Agios Pharmaceuticals, Inc. shares while 48 reduced holdings. 27 funds opened positions while 55 raised stakes. 45.70 million shares or 2.27% more from 44.69 million shares in 2017Q3 were reported. State Of Alaska Department Of Revenue holds 2,800 shares or 0% of its portfolio. 7,393 are held by Citigroup Inc. Artal Grp Sa accumulated 0.43% or 500,000 shares. Balyasny Asset Mgmt Ltd Liability Com owns 0.2% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 1.13M shares. Jennison Associate Lc invested 0.01% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Georgia-based Invesco Limited has invested 0.02% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). State Board Of Administration Of Florida Retirement System holds 0.01% or 54,983 shares. Gam Hldgs Ag has 0.04% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Pub Employees Retirement Association Of Colorado holds 0% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) or 6,769 shares. The Washington-based Parametric Limited Liability Corp has invested 0% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Pub Employees Retirement Sys Of Ohio, Ohio-based fund reported 17,833 shares. Tower Cap Lc (Trc) holds 0% or 68 shares in its portfolio. Federated Pa accumulated 9,093 shares. Bessemer Group Incorporated has invested 0% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Fernwood Management Ltd Liability Co has 0.84% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).

Since January 10, 2018, it had 1 insider purchase, and 23 insider sales for $18.55 million activity. $245,430 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares were sold by Biller Scott. The insider Schenkein David P sold $1.91M. 2,050 shares were sold by Hoerter Steven L., worth $173,533 on Thursday, March 22. Another trade for 6,800 shares valued at $557,396 was sold by Foster-Cheek Kaye I. $170,190 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares were sold by Bowden Christopher. Scadden David had bought 200 shares worth $16,688. On Friday, January 12 Alenson Carman sold $161,250 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) or 2,150 shares.

More notable recent Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) news were published by: Seekingalpha.com which released: “Agios Pharmaceuticals (AGIO) Investor Presentation – Slideshow” on May 04, 2018, also Seekingalpha.com with their article: “A Fresh Look At Celgene After Q1 And New Info On Ozanimod” published on May 08, 2018, Nasdaq.com published: “Agios Announces Revised Starting Time of 8:00am ET for Investor Day and First Quarter 2018 Financial Results …” on April 27, 2018. More interesting news about Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) were released by: Benzinga.com and their article: “The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap” published on April 29, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down” with publication date: May 04, 2018.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $4.94 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

Among 16 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 12 have Buy rating, 0 Sell and 4 Hold. Therefore 75% are positive. Agios Pharmaceuticals had 45 analyst reports since July 23, 2015 according to SRatingsIntel. The rating was maintained by Cowen & Co on Tuesday, August 1 with “Buy”. JP Morgan upgraded Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Monday, June 13 to “Overweight” rating. The company was maintained on Tuesday, August 1 by Oppenheimer. The firm has “Buy” rating given on Wednesday, March 30 by SunTrust. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has “Buy” rating given on Tuesday, June 6 by Cowen & Co. The stock has “Outperform” rating by Northland Capital on Thursday, July 23. As per Wednesday, April 11, the company rating was maintained by Credit Suisse. The company was initiated on Wednesday, March 2 by Janney Capital. Needham initiated Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Monday, October 24 with “Buy” rating. Credit Suisse maintained the stock with “Buy” rating in Thursday, February 15 report.

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. The company has market cap of $3.89 billion. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It currently has negative earnings. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.

More notable recent FibroGen, Inc. (NASDAQ:FGEN) news were published by: Globenewswire.com which released: “FibroGen Reports First Quarter 2018 Financial Results” on May 09, 2018, also Seekingalpha.com with their article: “FibroGen’s (FGEN) CEO Tom Neff on Q1 2018 Results – Earnings Call Transcript” published on May 10, 2018, Benzinga.com published: “Benzinga’s Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway” on May 09, 2018. More interesting news about FibroGen, Inc. (NASDAQ:FGEN) were released by: Nasdaq.com and their article: “FibroGen to Report First Quarter 2018 Financial Results on Wednesday, May 9, 2018” published on May 02, 2018 as well as Globenewswire.com‘s news article titled: “Consolidated Research: 2018 Summary Expectations for MGM Growth Properties, Reinsurance Group of America …” with publication date: April 27, 2018.

Among 8 analysts covering FibroGen Inc (NASDAQ:FGEN), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. FibroGen Inc had 18 analyst reports since July 29, 2015 according to SRatingsIntel. Citigroup initiated FibroGen, Inc. (NASDAQ:FGEN) on Wednesday, July 29 with “Buy” rating. The stock of FibroGen, Inc. (NASDAQ:FGEN) has “Hold” rating given on Thursday, March 29 by Mizuho. Mizuho initiated it with “Hold” rating and $61.0 target in Wednesday, October 4 report. Citigroup initiated FibroGen, Inc. (NASDAQ:FGEN) on Friday, December 4 with “Buy” rating. As per Tuesday, August 8, the company rating was maintained by Jefferies. Credit Suisse upgraded the shares of FGEN in report on Thursday, February 11 to “Outperform” rating. The stock of FibroGen, Inc. (NASDAQ:FGEN) earned “Neutral” rating by Credit Suisse on Thursday, January 21. As per Wednesday, September 23, the company rating was initiated by Lake Street. The rating was maintained by Stifel Nicolaus with “Buy” on Sunday, September 10. Goldman Sachs downgraded FibroGen, Inc. (NASDAQ:FGEN) on Friday, July 21 to “Neutral” rating.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Chart

Leave a Reply

Your email address will not be published. Required fields are marked *